EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Adherence to riluzole therapy in patients with amyotrophic lateral sclerosis in three Italian regions—The CAESAR study

Sabrina Giometto, Marco Finocchietti iD, Olga Paoletti, Niccolò Lombardi iD, Maria Grazia Celani, Francesco Sciancalepore, Ersilia Lucenteforte iD, Ursula Kirchmayer, CAESAR study group

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.5736 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Sabrina Giometto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Neuroprotective Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agenzia Italiana del Farmaco, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease. Riluzole may increase survival and delay the need for mechanical ventilation. The CAESAR project (‘Comparative evaluation of the efficacy and safety of drugs used in rare neuromuscular and neurodegenerative diseases’, FV AIFA project 2012‐2013‐2014) involves evaluating prescribing patterns, and analysing effectiveness and comparative safety of drugs, in patients with neurodegenerative diseases. The aim of this study is to evaluate adherence to riluzole in patients with ALS during the first year of use, identifying adherence clusters.

Methods

A retrospective cohort study was conducted using administrative data from Latium, Tuscany, and Umbria. We identified subjects with a new diagnosis of ALS between 2014 and 2019, with the first dispensation of riluzole within 180 days of diagnosis. We considered a two‐year look‐back period for the characterization of patients, and we followed them from the date of first dispensing of riluzole for 1 year. We calculated 12 monthly adherence measures, through a modified version of the Medication Possession Ratio, estimating drug coverage with Defined Daily Dose. Adherence trajectories were identified using a three‐step method: (1) calculation of statistical measures; (2) principal component analysis; (3) cluster analysis. Patient characteristics at baseline and during follow‐up were described and compared between adherence groups identified.

Results

We included 264 ALS patients as new users of riluzole in Latium, 344 in Tuscany, and 63 in Umbria. We observed a higher frequency of males (56.2%) and a mean age of 67.4 (standard deviation, SD, 10.4) in the overall population. We identified two clusters in all regions: one more numerous, including adherent patients (60%, 74%, 88%, respectively), and another one including patients who discontinued therapy (40%, 26%, 12%, respectively). In Tuscany patients discontinuing riluzole more frequently died (28.6% vs. 15.4%, p ‐value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisNeurodegenerative DiseasesNeuroprotective AgentsMaleHumansAgedRiluzoleRetrospective StudiesItaly

Stichwörter der Autor:innen

adherenceadministrative databasesamyotrophic lateral sclerosisriluzole

Substanzen

RiluzoleNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Department of Epidemiology, ASL Roma 1, SSR Lazio, Rome, Italy.
  • Regional Health Agency of Tuscany, Florence, Italy.
  • Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
  • Hospital of Perugia, Neurophysiopathology, Perugia, Italy.
  • National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.

ORCID-Profile: Marco Finocchietti, Niccolò Lombardi, Ersilia Lucenteforte

Förderung

  • Agenzia Italiana del Farmaco, Ministero della Salute

Zitieren

APA

Giometto, S., Finocchietti, M., Paoletti, O., Lombardi, N., Celani, M. G., Sciancalepore, F., Lucenteforte, E., Kirchmayer, U., & CAESAR study group (2024). Adherence to riluzole therapy in patients with amyotrophic lateral sclerosis in three Italian regions—The CAESAR study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5736

Vancouver

Giometto S, Finocchietti M, Paoletti O, Lombardi N, Celani MG, Sciancalepore F, et al. Adherence to riluzole therapy in patients with amyotrophic lateral sclerosis in three Italian regions—The CAESAR study. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5736

BibTeX
@article{Giometto2024,
  author = {Giometto, Sabrina and Finocchietti, Marco and Paoletti, Olga and Lombardi, Niccolò and Celani, Maria Grazia and Sciancalepore, Francesco and Lucenteforte, Ersilia and Kirchmayer, Ursula and CAESAR study group, CAESAR study group},
  title = {Adherence to riluzole therapy in patients with amyotrophic lateral sclerosis in three Italian regions—The CAESAR study},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.5736}
}
Kostenlos starten →